Infections, Meningococcal Clinical Trials

Completed

A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

NCT05082285

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations: GSK Investigational Site Santo Domingo Este, Dominican Republic

GSK Investigational Site Espoo, Finland

GSK Investigational Site Helsinki, Finland

GSK Investigational Site Jarvenpaa, Finland

View all 33 locations

View Trial Details

Completed

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

NCT03621670

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +12 more
Locations: GSK Investigational Site Birmingham, Alabama, United States

GSK Investigational Site Fayetteville, Arkansas, United States

GSK Investigational Site Jonesboro, Arkansas, United States

GSK Investigational Site Anaheim, California, United States

View all 57 locations

View Trial Details

Completed

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

NCT04886154

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations: GSK Investigational Site Colorado Springs, Colorado, United States

GSK Investigational Site Longmont, Colorado, United States

GSK Investigational Site Doral, Florida, United States

GSK Investigational Site Miami Lakes, Florida, United States

View all 53 locations

View Trial Details

Completed

Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

NCT04318548

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations: GSK Investigational Site Phoenix, Arizona, United States

GSK Investigational Site Bell Gardens, California, United States

GSK Investigational Site Los Angeles, California, United States

GSK Investigational Site Oakland, California, United States

View all 53 locations

View Trial Details

Completed

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

NCT04502693

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations: GSK Investigational Site Chandler, Arizona, United States

GSK Investigational Site Glendale, Arizona, United States

GSK Investigational Site Jonesboro, Arkansas, United States

GSK Investigational Site Bell Gardens, California, United States

View all 112 locations

View Trial Details

Completed

Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine

NCT01939158

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations: Canberra Hospital Garran, Australian Capital Territory, Australia

The Childrens Hospital at Westmead Westmead, New South Wales, Australia

Women's and Children's Hospital North Adelaide, South Australia, Australia

Vaccine and Immunization Research Group Melbourne, Victoria, Australia

View all 51 locations

View Trial Details

Completed

Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612

NCT00955682

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations: GSK Investigational Site Espoo, Finland

GSK Investigational Site Helsinki, Finland

GSK Investigational Site Helsinki, Finland

GSK Investigational Site Jarvenpaa, Finland

View all 14 locations

View Trial Details

Completed

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age

NCT03652610

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations: GSK Investigational Site Blacktown, New South Wales, Australia

GSK Investigational Site Kanwal, New South Wales, Australia

GSK Investigational Site Gold Coast, Queensland, Australia

GSK Investigational Site Sherwood, Queensland, Australia

View all 30 locations

View Trial Details

Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines

NCT01144663

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations: GSK Investigational Site Haabneeme, Estonia

GSK Investigational Site Tallinn, Estonia

GSK Investigational Site Tallinn, Estonia

GSK Investigational Site Tallinn, Estonia

View all 44 locations

View Trial Details

Completed

Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children

NCT01266993

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations: GSK Investigational Site Draguignan, France

GSK Investigational Site Le Havre, France

GSK Investigational Site Lingolsheim, France

GSK Investigational Site Miribel, France

View all 24 locations

View Trial Details

Infections, Meningococcal

Infections, Meningococcal trial results

Related conditions